Advertisement


Charles L. Loprinzi, MD, on Olanzapine for Prevention of CINV

2015 Palliative Care in Oncology Symposium

Advertisement

Charles L. Loprinzi, MD, of the Mayo Clinic, discusses olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy (Abstract 176).



Related Videos

Pain Management

Judith Paice, PhD, RN, on Neuropathic Pain

Judith Paice, PhD, RN, of Northwestern University, reviews the current principles on assessing and treating neuropathic pain in cancer.

Palliative Care

Kathleen Foley, MD, on Palliative Care in Low-Resource Settings

Kathleen Foley, MD, of Memorial Sloan Kettering Cancer Center, discusses the challenges of integrating palliative care in areas without sufficient resources or health-care infrastructure.

Palliative Care

Kathleen Elizabeth Bickel, MD, MPhil, on Defining High-Quality Palliative Care in Oncology Practice

Kathleen Elizabeth Bickel, MD, MPhil, of the White River Junction VA Medical Center, discusses the ASCO/AAHPM Guidance Statement, which will help oncology providers enhance their delivery of palliative care (Abstract 108).

Symptom Management
Palliative Care

Lawrence H. Einhorn, MD, on CINV Clinical Trial Results: The Alliance A221301 Study

Lawrence H. Einhorn, MD, of Indiana University Simon Cancer Center, discusses the encouraging study findings on olanzapine for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy (Abstract 176).

Palliative Care
Symptom Management

Eduardo Bruera, MD, on Cachexia Assessment and Management State of the Art

Eduardo Bruera, MD, of The University of Texas MD Anderson Cancer Center, discusses exciting developments in the assessment and management of cachexia, as well as a number of emerging pharmacologic and nonpharmacologic interventions (Abstract 67).

Advertisement

Advertisement




Advertisement